Storia in 3 fonti

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.

Raccontata da

biopharmadive.com

benzinga.com

economictimes.indiatimes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo15 h fa

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics surged 85% after Q2 earnings; Deramiocel gene therapy for DMD is advancing BLA with FDA, manufacturing facility ready. FDA approval is critical—$237.9M cash covers only 12 months, making regulatory clarity essential for commercial launch.

originale

economictimes.indiatimes.com14 h fa

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares jumped 77% after FDA agreed to review new data on deramiocel for Duchenne muscular dystrophy. The review extension stretches runway; $237.9M cash allows controlled spending through the three-month review—a key survival metric for biotech under approval pressure.

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Confronto fonti

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Timeline cronologica

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes